Fluticasone furoate, umeclidinium and vilanterol once-daily single inhaler triple therapy

Description

In this Product Explainer, Respiratory Physician Dr Adrian Barnett explains the role of fluticasone furoate, umeclidinium and vilanterol once-daily single inhaler triple therapy for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-240005 Approved September 2024.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Karam Kostner

A/Prof Karam Kostner

LDL Management – Why it is Important

A/Prof Ralph Audehm

A/Prof Ralph Audehm

Navigating Expanded PBS Access to SGLT2i in General Practice

Prof Deborah Bateson

Prof Deborah Bateson

Cervical Cancer Screening 2025

Clinical A/Prof Greg Katsoulotos

Clinical A/Prof Greg Katsoulotos

Asthma Cases – When to Use Dual vs Triple Therapy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Adrian Barnett

expert

Dr Adrian Barnett

Respiratory Physician, Gold Coast University Hospital

Date published: 12 November 2024